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MinireviewGetting at the Root
and Stem of Brain Tumors
monly expressed genes suggests a more intimate rela-
tionship between these cells.
In fact, the similarity between brain tumors and neural
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For example, the Sonic hedgehog (Shh) pathway plays
a critical role in regulating growth of neural progenitors
and has been implicated in the etiology of brain tumors.
Brain tumors are among the most aggressive and in- In the cerebellum, Shh is required for proliferation of
tractable types of cancer. Recent studies indicate that granule cell precursors, and mutations in this pathway
brain tumor cells resemble neural stem cells in terms predispose to cerebellar tumors (medulloblastomas) in
of phenotype, signaling, and behavior in vitro. In light both mice and humans (reviewed in Wechsler-Reya,
of these similarities, it has been suggested that brain 2003). Recent studies suggest that Shh signaling may
tumors arise from stem cells, that they co-opt stem also regulate self-renewal of progenitors in other parts
cell strategies for self-renewal, and even that they of the brain, including the subventricular zone, hippo-
contain “cancer stem cells” that are critical for tumor campus, and olfactory bulb (Lai et al., 2003; Machold
maintenance. We will examine these possibilities and et al., 2003). These findings raise the possibility that Shh
discuss their implications for the understanding and pathway activation may be involved in tumors besides
treatment of brain tumors. medulloblastoma. Although a small percentage of glial
tumors (gliomas) exhibit amplification of the Shh-respon-
Due to their rapid growth and tendency to spread sive transcription factor Gli1, no other Shh pathway mu-
throughout the brain and spinal cord, brain tumors are tations have been found in these tumors. However, at
extremely difficult to treat and often fatal. Of the 18,000 least one report suggests that hedgehog pathway genes
Americans diagnosed with primary malignant brain tu- are expressed in gliomas and that growth of glioma
mors each year, only one-third will survive beyond 5 cell lines is reduced by pharmacological inhibitors of the
years (American Cancer Society, 2004). Glioblastoma pathway (Dahmane et al., 2001). In light of recent evidence
multiforme, the most common brain tumor in adults, has that ligand-dependent (and mutation-independent)
a mean survival time of 10–12 months. Medulloblas- hedgehog pathway activation contributes to tumorigen-
toma, the most common malignant brain tumor in chil- esis in other tissues (Berman et al., 2003), the role of
dren, has a more favorable prognosis: combinations of Shh signaling in other brain tumors merits further study.
radiation, chemotherapy, and surgery can cure more The Wnt pathway, which is critical for self-renewal
than half of patients. However, children who survive of hematopoietic and epithelial stem cells (Reya et al.,
medulloblastoma treatment often suffer severe cogni- 2001), may also be involved in the growth of NSCs and
tive and physical deficits and increased susceptibility brain tumors. Recent reports show that -catenin, a
to other cancers. To develop more effective therapies central mediator of Wnt signaling, is important for NSC
for these tragic diseases, we need a deeper understand- and progenitor cell proliferation throughout the CNS.
ing of their molecular and cellular basis. Recent studies Conditional deletion of -catenin causes depletion of
suggest that this understanding may come from an ap- neuronal precursors in the ventricular zone, whereas
overexpression of activated -catenin results in massivepreciation of the relationship between brain tumors and
expansion of the precursor pool and enlargement of theneural stem cells (NSCs).
hindbrain, midbrain, and forebrain (Chenn and Walsh,Genes and Signals Shared by Brain Tumors
2002; Zechner et al., 2003). Activation of the Wnt path-and Stem Cells
way is also associated with brain tumors. In particular,The fact that brain tumors frequently include a mixture
a subset of medulloblastomas has been reported toof neuronal and glial cell types has often been cited as
harbor mutations in -catenin, Axin, or APC (Wechsler-evidence that these tumors may contain multipotent
Reya, 2003). Since these tumors have a distinct pheno-progenitors. Consistent with this notion, many brain tu-
type and molecular profile from medulloblastomas asso-mors contain cells that express markers of neural stem
ciated with hedgehog pathway mutations, they maycells (Hemmati et al., 2003; Ignatova et al., 2002; Leung
arise from a distinct set of progenitors. To date, thereet al., 2004; Singh et al., 2003). The most common exam-
have been no reports of Wnt pathway mutations in brainple of a shared antigen is the intermediate filament pro-
tumors outside the cerebellum. However, given the im-tein nestin, which is expressed in NSCs in the developing
portance of Wnt signaling in self-renewal of progenitorsand adult CNS and has also been found in brain tumors
throughout the brain, it is worth considering whetherand brain tumor-derived cell lines. Recent studies have
dysregulation of this pathway occurs in other types ofreinforced this correlation by describing expression of
brain tumors as well.other NSC markers—including CD133, musashi-1,
Other genes that may control self-renewal of bothbmi-1, and sox-2—in primary brain tumor cells. Although
brain tumors and neural stem cells include the polycombthe phenotypic similarities between brain tumors and
transcription factor Bmi-1 and the phosphatase PTEN.NSCs could be coincidental, the growing list of com-
Bmi-1 regulates self-renewal of progenitors in the cen-
tral and peripheral nervous systems (Molofsky et al.,
2003), in part by repressing genes (such as p16Ink4a*Correspondence: rw.reya@duke.edu
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Figure 1. The Relationship between Brain
Tumors and Neural Stem Cells
Brain tumors (red) share many characteristics
with NSCs (yellow), including expression of
intracellular and cell surface markers, acti-
vation of signaling pathways, and an ability
to form self-renewing, multipotent neuro-
spheres in vitro. One explanation for these
similarities is that brain tumors result from
transformation of NSCs, and there is evi-
dence from transgenic mice to support this
possibility. However, brain tumors may also
arise from transformation of more restricted
progenitors; in this case, the similarities in
gene expression might represent acquisition
of stem cell characteristics as a consequence
of transformation. In either case, cells with
stem cell-like properties are likely to be criti-
cal for growth of brain tumors, and targeting
these cells may represent an important ave-
nue for therapy.
and p19Arf) that promote cellular senescence and cell In interpreting these studies, it is important to consider
the possibility that prolonged culture of progenitors indeath. In addition, bmi-1 has recently been shown to
be a target of the Shh signaling pathway and to be high concentrations of growth factors may cause cells
to adopt fates that they would not normally adopt inrequired for self-renewal of neural progenitors in the
cerebellum (Leung et al., 2004). Thus, elevated expres- situ, or select for a subset of cells that does not reflect
the behavior of the original population (Gabay et al.,sion of bmi-1 in medulloblastoma and other brain tumors
(Hemmati et al., 2003; Leung et al., 2004) may reflect an 2003). Thus, culture of brain tumor cells under neuro-
sphere-generating conditions may dramatically alterincreased capacity for self-renewal. PTEN is one of the
most frequently mutated genes in primary glioblastoma their capacity for self-renewal and differentiation. Study-
ing tumor cells that have not been subjected to extensive(Li et al., 2003). Recent studies of mice in which PTEN
has been conditionally deleted in nestin-expressing pre- culture in growth factors may help shed light on their
intrinsic properties. Notwithstanding these caveats, thecursors suggest that it is a critical negative regulator of
NSC proliferation and survival (Groszer et al., 2001). In demonstration of functional similarities between brain
tumor cells and NSCs represents an important step be-addition, studies of PTEN/ mice suggest that this gene
may also be important for NSC migration (Li et al., 2003). yond phenotypic characterization and brings us closer
to understanding how these cells may be related toThus, dysregulation of PTEN may contribute to the ag-
gressive growth and metastatic behavior associated one another.
Do Brain Tumors Arise from Neural Stem Cells?with gliomas.
Self-Renewal and Multipotency of Brain Tumors One explanation for the resemblance between brain tu-
mors and stem cells is that brain tumors result fromand Stem Cells
The similarities in phenotype and signaling between transformation of NSCs (see Figure 1). But does the fact
that brain tumor cells look and act like NSCs mean thatbrain tumor cells and stem cells may reflect similarities
in their cellular behavior. Support for this notion comes they actually arise from them? Or can they result from
acquisition of stem cell characteristics by more differen-from recent studies by Ignatova et al. (2002), Hemmati
et al. (2003), and Singh et al. (2003). These investigators tiated progenitors? There is evidence for both possibil-
ities.isolated cells from primary human brain tumors (includ-
ing astrocytomas, glioblastomas, and medulloblasto- Support for the notion that brain tumors can arise
from transformation of neural stem cells comes frommas) and showed that, like NSCs, they form clonal neu-
rospheres that can be repeatedly passaged in vitro. mouse models in which expression of oncogenes or
tumor suppressors is perturbed in an NSC-specific man-Upon withdrawal of growth factors, tumor-derived neu-
rospheres can differentiate into both neurons and glia, ner. For example, Holland and colleagues have gener-
ated mice that express the avian retrovirus receptorconsistent with the heterogeneous cell types found in
the tumors from which they were derived. Although brain (TVA) in nestin cells, and then used avian retroviruses
to deliver oncogenes into neural stem cells (reviewed intumors have long been known to contain a mixture of
neurons and glia, it has been unclear whether all of Holland, 2001). Using this system, they have shown that
transduction of constitutively active epidermal growththese cells are derived from the tumor or whether some
represent normal cells that have become trapped within factor receptor, oncogenic Ras and Akt, or platelet-
derived growth factor into forebrain nestin progenitorsthe tumor matrix. The observation that brain tumor-
derived neurospheres can generate multiple cell types results in tumors that resemble human gliomas. Simi-
larly, intracerebellar injection of retroviruses carryingsuggests that the heterogeneity within brain tumors may
be an inherent characteristic of the tumor. Together, shh and c-myc can cause medulloblastoma in nestin-
TVA mice (Rao et al., 2003). To the extent that transgenethese studies suggest that brain tumor cells share with
neural stem cells the capacity for self-renewal and multi- expression in these mice is restricted to neural stem
cells (nestin expression has also been observed in morelineage differentiation.
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committed progenitors), these studies suggest that detection and diagnosis. Finally, targeting of this cell
NSCs can serve as targets of transformation in brain may be necessary (and perhaps even sufficient) to dis-
tumors. rupt the growth of the tumor.
But there is also evidence that brain tumors can result The studies described above suggest that brain tu-
from transformation of more differentiated cells. Shh mors and neural stem cells resemble one another at
pathway-associated medulloblastomas in both mice a cellular and molecular level. Whether brain tumors
and humans have a phenotype and gene expression actually arise from NSCs in most cases remains unclear,
profile that strongly resembles that of committed gran- and a definitive answer may have to await the develop-
ule cell precursors (Wechsler-Reya, 2003). Moreover, in ment of better markers for neural stem cells and progeni-
studies using the TVA system, gliomas can be generated tors. Nevertheless the fact that these cells express simi-
by retroviral transduction of genes into GFAP glial lar genes and show activation of similar signaling
progenitors as well as nestin NSCs (Holland, 2001). pathways suggests that they use similar strategies to
Expression of oncogenic Ras or SV40 T antigen under achieve self-renewal and to generate heterogeneous
the control of a GFAP promoter also results in gliomas populations of cells within a tissue. Understanding stem
in a large percentage of animals (Ding et al., 2001; Xiao cell signaling pathways and developing ways to manipu-
et al., 2002). Finally, transgenic mice expressing v-erbB late them will be critical in our effort to develop new
driven by an S100- promoter (which is active in glial treatments for tumors of the nervous system.
precursors) develop oligodendrogliomas (Weiss et al.,
2003). These studies strongly suggest that restricted Selected Reading
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